Clinical omics

A.A. 2021/2022
6
Crediti massimi
48
Ore totali
SSD
MED/06 MED/11 MED/15
Lingua
Inglese
Obiettivi formativi
Non definiti
Risultati apprendimento attesi
Non definiti
Programma e organizzazione didattica

Edizione unica

Responsabile
More specific information on the delivery modes of training activities for academic year 2021/22 will be provided over the coming months, based on the evolution of the public health situation
Programma
2 CFU: Omics in Oncology (16 hours)
Clinical applications of omics technologies:- 4 hours
· Omics in cancer medicine
· Gene signature
· Prognostic and predictive gene signatures
The molecular tumor board:- 3 hours
· Role of the molecular tumor board
· Structure
· Reporting
· Data integration
Patient stratification and enrichement strategies in clinical trials- 4 hours
· Use of omic to stratify patients in clinical trials
· Umbrella trials vs basket trials
Clinical trial design and disease risk-assessment- 2 hours
· Enrichment trials
· Genomics signature in context of clinical trials and application in clinical practice
New tools for disease monitoring: the role of liquid biopsy :- 2 hours
· Prognostic role of circulating tumor DNA
· Predictive role of liquid biopsy

2 CFU: Omics in Hematological Malignancies (16 hours)
Clinical applications of omics technologies in Hematology:- 4 hours
· What is a biomarker? Types of biomarkers.
· Molecular diagnostic testing.
· Driver vs. passenger mutations
· Actionable molecular alterations
· .
· Genomic online resources
NGS and clinical decision making in Hematology:- 4 hours
Patient stratification and enrichement strategies in clinical trials:- 4 hours
· Use of omic to stratify patients in clinical trials
· Umbrella trials vs basket trials
· Disease and clonal evolution
Clinical trial design and disease risk-assessment:- 2 hours
· Enrichment trials
· Genomics signature in context of clinical trials and application in clinical practice
New tools for disease monitoring Alessandro - 2 hours
· Liquid biopsy and circulating biomarkers
1 CFU: Cardio-Genomics (8 hours)
Biomarkers in patient risk assessment: - 3 hours
Omic biomarkers for cardiovascular risk assessment
Patient risk stratification: - 3 hours
· Integration of omics to predict the risk of cardiovascular disease
Clinical trial design and cardio-toxicity risk-assessment: - 2 hours
Quality and outcome indicators
· Integration of big data and omics to predict cardio-toxicity
1 CFU: Neurogenomics (8 hours)
Neorogenomics in clinical setting:- 3 hours
· NGS approach to study Mitochondrial DNA
· Genes and neurological disease: Genotype and Phenotype correlation
Omics-based biomarkers for early diagnosis of neurodegenerative disorders - 3 hours
· Genomics of neurodegenerative disorders
Clinical trial design and risk-assessment for brain tumors: - 2 hours
How to design an clinical study in rare neurological diseases
· Emerging omics data in brain tumors
Prerequisiti
No prior knowledge is required.
Metodi didattici
Lectures will be accompanied by practicals, working gropu and time for reflection and collective discussion.
Materiale di riferimento
Slides and scientific material provided during lectures
Modalità di verifica dell’apprendimento e criteri di valutazione
The examination is based on a multiple-choice test. We will ask 30 multiple choice questions and a minimum of 18 correct answers will be required to pass the examination
Attendance is required to be allowed to take the exam. Unexcused absence is tolerated up to 30% of the course activities
MED/06 - ONCOLOGIA MEDICA - CFU: 0
MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE - CFU: 0
MED/15 - MALATTIE DEL SANGUE - CFU: 0
Lezioni: 48 ore
Docente/i
Ricevimento:
su appuntamento
via L. Temolo 4, 20126 Milano (6° piano)